AzTrials
AzTrials

Women's HealthPLAN-RTNCT07787533

Digital Resistance Training for Midlife Women Using GLP-1

A study testing PLAN-RT 1.0 in people with Women's Health and Obesity & Overweight, run by Louisiana State University and A&M College at 1 site in United States.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record

Search all trials

Trial summary

The goal of PLAN-RT 1.0 to learn if a 12-week app-based strength training program can help midlife women build and stick with a regular strength training routine while they are taking GLP-1 medication for weight loss. Read more about this study

Who is it for?
Ages 40 to 59 years, women only
What is being tested?
PLAN-RT 1.0
Could I receive a placebo?
No, everyone receives an active treatment
How many people
15 participants
Where
1 siteUnited States
Study dates
1 Nov 2026to 30 Jun 2027
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 59 years
  • Women only
  • No healthy volunteers
  • Adult

Inclusion Criteria: Participants must meet all of the following criteria:

  • Female, age 40 to 54 years.
  • Recently initiated GLP-1 receptor agonist (GLP-1RA) therapy within the past 6 months.
  • Body mass index (BMI) ≥27 kg/m².
  • Not currently participating in regular resistance training (self-reported absence of regular resistance training during the previous month).
  • Able to stand, sit, and perform bodyweight movements without assistive devices.
  • Owns a compatible smartphone (iOS or Android) with cellular or Wi-Fi access and is willing to use study applications.
  • Able to read, understand, and provide informed consent in English.
  • Willing and able to attend required in-person study visits.

Exclusion Criteria: Participants will be excluded if they meet any of the following criteria:

  • Plans to discontinue GLP-1RA therapy or substantially modify treatment during the 12-week study period.
  • Self-reported musculoskeletal injury, orthopedic limitation, or surgery within the previous 6 months that would contraindicate resistance training participation.
  • Self-reported unstable cardiovascular disease or cardiac event within the previous 6 months.
  • Currently pregnant or planning to become pregnant during the study period.
  • Active eating disorder or psychiatric condition that may interfere with study participation.
  • Unable to use smartphone applications required for the intervention.
  • Current participation in another pharmacological, behavioral, weight management, or chronic disease management program that could confound study outcomes.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Kimberly Allen contact

225-578-2363

kmallen@lsu.edu

United States1 site
  • Louisiana State University School of Kinesiology

    Baton Rouge, Louisiana, 70803

    Shiyu Li, Ph.D., 225-578-0977, sli40@lsu.edu

    Kimberly M Allen, M.A., 225-578-2363, kmallen@lsu.edu

Other trials in United States

About this study

Official title: Developing a Scalable Digital Resistance Training Intervention to Preserve Muscle Function in Midlife Women Receiving GLP-1 Therapy

The goal of PLAN-RT 1.0 to learn if a 12-week app-based strength training program can help midlife women build and stick with a regular strength training routine while they are taking GLP-1 medication for weight loss. PLAN-RT 1.0 targets women ages 40 to 59 who were not regularly exercising before starting GLP-1 medication.

The main questions this study aims to answer are: (1) Is the PLAN-RT 1.0 program feasible and acceptable to participants (based on how many people join, stay in the study, and use the program)? (2) Does the program lead to early changes in muscle strength, body composition, physical function, and exercise habits?

Read the detailed description

GLP-1 receptor agonist (GLP-1RA) therapies have emerged as highly effective pharmacological treatments for obesity, yet weight loss achieved through these agents is accompanied by significant lean mass loss. This is particularly relevant for midlife women who are concurrently vulnerable to age- and menopause-related declines in skeletal muscle mass and physical function. Resistance training (RT) is recommended as an evidence-based strategy for preserving lean mass during weight loss treatments, yet no theory-grounded, scalable intervention exists to support RT initiation and maintenance in midlife women. PLAN-RT 1.0 is a 12-week, app-delivered resistance training intervention developed for midlife women (aged 40-59) receiving GLP-1RA therapy for obesity. The intervention integrates three complementary theoretical frameworks - Self-Regulation Theory (initiation), Habit Formation Theory (cue-behavior-reward), and the Affective Response Theory (intrinsic reinforcement) - operationalized through a structured set of behavior change techniques delivered via digital health technologies. This proposed single-arm feasibility pilot (n=15) pursues two specific aims. Aim 1 evaluates the feasibility and acceptability of PLAN-RT 1.0 using pre-specified benchmarks across enrollment, adherence, retention, and ecological momentary assessment (EMA) response rate, alongside exploratory pre-post analyses of body composition, muscle strength and physical function, and behavioral outcomes. Aim 2 examines the mechanistic role of affective response to RT as a driver of habit formation, using EMA-based per-session affective valence data and mixed methods to characterize how GLP-1RA-mediated dopaminergic changes may alter the intrinsic reward signal from exercise. Feasibility benchmarks, variance estimates, and mechanistic insights from PLAN-RT 1.0 will directly inform the development of PLAN-RT 2.0 through an R21 factorial optimization trial (MOST framework) and ultimately an R01 efficacy trial, establishing a scalable clinical tool for lean mass preservation in midlife women receiving GLP-1RA therapy.

Being tested
PLAN-RT 1.0
Keywords
resistance training, women's health, obesity, perimenopausal women, digital intervention
Medical subject headings
Obesity, Overweight

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PLAN-RT 1.0Behavioural

    A 12-week theory-based, app-delivered resistance training behavioral intervention incorporating behavior change techniques based on Self-Regulation Theory and Habit Formation Theory to promote initiation and maintenance of resistance training among midlife women receiving GLP-1RA therapy. The intervention includes exercise instruction, goal setting, action planning, contextual cues, self-monitoring, and feedback delivered through integrated digital health technologies.

Study groups in NCT07787533
Study groupRoleWhat they receive
PLAN-RT 1.0ExperimentalParticipants will receive PLAN-RT 1.0, a 12-week digitally delivered resistance training intervention designed for physically inactive midlife women (ages 40-59 years) who have recently initiated GLP-1 receptor agonist (GLP-1RA) therapy. The intervention combines a Fitbit Versa smartwatch, LIT AXIS™ smart resistance band, and smartphone applications integrated through the Pathverse platform to support resistance training participation. Participants will receive exercise instruction and form guidance, personalized resistance training goal setting, implementation intention-based action planning, contextual prompts delivered through smartwatch notifications, self-monitoring of exercise behavior, and feedback on goal attainment. Resistance training activities include bodyweight and resistance band exercises performed according to a structured progressive program over 12 weeks.
Receives: Behavioral: PLAN-RT 1.0

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of adults screened (Participants)

    Number of adults screened for eligibility for the study

    Measured: Weekly throughout recruitment

  2. Intervention Acceptability (CSQ-8)

    Acceptability will be assessed using the Client Satisfaction Questionnaire-8 (CSQ-8). Higher scores indicate greater participant satisfaction with the intervention. Score on a scale, typically 0-32 for CSQ-8

    Measured: Week 12

  3. Number of Adults Enrolled (Participants)

    Number of adults who met eligibility criteria and enrolled in the study

    Measured: Weekly throughout recruitment

  4. Retention Rate (Percentage of enrolled participants)

    Proportion of enrolled participants who completed the 12-week study

    Measured: Week 4, 8, 12

Secondary outcomes (2)
  1. Change in Body Weight in Kilograms

    Body weight will be measured using a calibrated digital scale in kilograms. Change from baseline to Week 12 will be evaluated.

    Measured: Baseline and Week 12

  2. Intervention Usability (SUS)

    Usability will be assessed using the System Usability Scale (SUS). Scores range from 0 to 100, with higher scores indicating greater usability.

    Measured: Week 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Aug 2026
  2. Study start1 Nov 2026 (estimated)
  3. Primary completion30 Jun 2027 (estimated)
  4. Study completion30 Jun 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Model description
This is a single-arm feasibility pilot study. All enrolled participants will receive the same 12-week app-delivered resistance training intervention (PLAN-RT 1.0); there is no control or comparison group. This design was selected to first establish feasibility, acceptability, and preliminary outcome signals of the intervention before proceeding to a larger controlled trial. The intervention integrates a smartwatch, resistance band, and smartphone applications to deliver personalized goal setting, action planning, contextual prompts, self-monitoring, and feedback, grounded in Self-Regulation Theory and Habit Formation Theory.
Masking
None (open label)
Enrolment
15 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07787533
Sponsor's protocol ID
AM260036
Acronym
PLAN-RT
Status last verified
Aug 2026
First submitted
17 Aug 2026
Last updated
26 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in